1	Title: A Caveat to Using Wearable Sensor Data for COVID-19 Detection: The Role of
2	Behavioral Change after Receipt of Test Results
3	
4	Authors: Jennifer L. Cleary, ^{1,2,5} Yu Fang ^{1,5} , Srijan Sen ^{1,3} , Zhenke Wu* ⁴
5	
6	Affiliations
7	¹ Michigan Neuroscience Institute, University of Michigan, Ann Arbor, MI;
8	² Department of Psychology, University of Michigan, Ann Arbor, MI;
9	³ Department of Psychiatry, University of Michigan Medical School;
10	⁴ Department of Biostatistics, University of Michigan, Ann Arbor, MI;
11	⁵ These authors contributed equally: Jennifer L. Cleary, Yu Fang.
12	
13	Corresponding author
14	Zhenke Wu, PhD. Department of Biostatistics, University of Michigan. 1415 Washington
15	Heights, Ann Arbor, MI, 48109-2029, USA; telephone (734) 764-7067; e-mail:
16	zhenkewu@umich.edu
17	
18	Word, Table, and Figure Count
19	Abstract, 147 words; main, 1489 words; 2 figures; 2 extended data figures.
20	
21	
22	
23	

24 Abstract:

25	Recent studies indicate that wearable sensors have the potential to capture subtle
26	within-person changes that signal SARS-CoV-2 infection. However, it remains unclear
27	the extent to which observed discriminative performance is attributable to behavioral
28	change after receiving test results. We conducted a retrospective study in a sample of
29	medical interns who received COVID-19 test results from March to December 2020. Our
30	data confirmed that sensor data were able to differentiate between symptomatic
31	COVID-19 positive and negative individuals with good accuracy (area under the curve
32	(AUC) = 0.75). However, removing post-result data substantially reduced discriminative
33	capacity (0.75 to 0.63; delta= -0.12, p=0.013). Removing data in the symptomatic period
34	prior to receipt of test results did not produce similar reductions in discriminative
35	capacity. These findings suggest a meaningful proportion of the discriminative capacity
36	of wearable sensor data for SARS-CoV-2 infection may be due to behavior change after
37	receiving test results.
38	
39	
40	
41	
42	
43	
44	
45	
46	

47 Main

48 Recent studies ^{1–4} suggest enormous public health potential of wearable sensors in 49 capturing subtle within-person changes that indicate an infection, such as by SARS-50 CoV-2. Detection of infection via wearable data provides a potentially effective, scalable 51 method of infection surveillance, through passive, non-invasive methods ⁵. However, 52 the assessments of wearable sensors for SARS-CoV-2 infection to date conflate two 53 distinct streams of information - direct physiologic effects of infection and behavioral 54 changes secondary to learning confirmation of infection through receipt of test results. 55 Understanding the relative importance of these two streams of information in infection detection is critical to determining if infection surveillance may be possible through 56 57 wearable technology. This paper seeks to further this understanding by leveraging a 58 unique data set with individual-level dates of receiving test results that are linked to 59 wearable data collected from a cohort of symptomatic COVID-19 positive or negative medical interns. 60

61

62 The Intern Health Study is a prospective cohort study that assesses mental health 63 during the first year of residency training ^{6,7}. Individuals starting residency in the 2019 and 2020 cohorts were invited to take part. Participating interns received a Fitbit Inspire 64 65 HR or Charge 3 device (or \$50 if they already have a Fitbit, Fitbit Inc., San Francisco, 66 CA; or an Apple Watch, Apple Inc., Cupertino, CA) and \$60 in compensation. The 67 institutional review board at the University of Michigan approved the study. From April to December 2020, participants were sent multiple surveys that assessed whether they 1) 68 exhibited any symptoms consistent with COVID-19 (e.g. fever, cough, shortness of 69

breath, headache); (2) were tested for SARS-CoV-2 infection; (3) tested positive. Daily
sleep duration, physical activity, and resting heart rate (RHR) were measured through
Fitbit or Apple Watch throughout the first internship year. We focused on interns
because this is a population that is likely to receive tests, receive test results quickly,
and are more adherent to quarantine measures.

75

76 A total of 3,532 subjects participated in the 2019 and 2020 cohorts of Intern Health 77 Study. Among them, 506 subjects experienced COVID-19-like symptoms between 78 March 15 and December 2020 and of these, 379 reported being tested for SARS-CoV-79 2. There were 94 individuals who tested positive ("cases") and 285 individuals who 80 tested negative ("controls"). We included in the analysis 22 cases and 83 controls who 81 had step, sleep, and RHR data available for more than 50% of the days during baseline 82 (21 to 7 days prior to symptom onset) and test (0-7 days after symptom onset) periods. 83 respectively (Extended Data Figure 1). Participants were on average 28.5 +/- 2.81 years of age, and 50.5% (n = 53) of the sample were female. 84

85

Our results are consistent with those reported by Quer et al. (2020)², validating the value of passive wearable sensor data in differentiating symptomatic COVID-19 positive from negative individuals. In particular, we followed Quer et al. (2020)² and used externally-constructed metrics that operationalize within-person changes in RHR, sleep, steps and all three combined. The metrics effectively contrast an individual's wearable sensor data from the test period with those from the baseline period, which are then used to discriminate cases and controls. Using all the data in baseline and test periods

93	(Figure 1a), we observed that metrics of within-individual change discriminated cases
94	from controls except for RHR (Figure 2, a-d). Sleep minutes increased more among
95	cases than controls after symptom onset (mean change: 47.9 in cases, 16.6 in controls
96	p=0.044; area under the curve, AUC, based on SLEEPmetric = 0.66, 95% confidence
97	interval, CI = 0.51-0.80). Cases reduced physical activity more than controls after
98	symptom onset (mean change: -3,703 in cases, -1,038 in controls, p=0.002; AUC based
99	on STEPmetric = 0.75 , 95% CI = $0.63-0.87$). Mean change in RHR is higher in the
100	cases (1.3 in cases, 0.4 in controls, p=0.18) with the lowest discriminative ability based
101	on RHRmetric (AUC = 0.63, 95% CI = 0.48-0.79). The combined metric based on all
102	wearable sensor data results in an AUC of 0.75 (95% CI = 0.62-0.89).
103	
104	To test whether the realized AUCs were mainly driven by the subset of data after receipt
105	of test results, we conducted an analysis that removed data points on and after the
106	result delivery date (Figure 1b). Compared with the previous analysis, we observed
107	worse discriminative ability (Figure 2e-2h) by SLEEPmetric (AUC = 0.60, 95% CI =
108	0.42-0.76), STEPmetric (AUC = 0.63, 95% CI = 0.49-0.78), and combined sensor
109	metrics (AUC = 0.68, 95% CI = 0.50-0.82), but similar performance in RHR (AUC =
110	0.66, 95% CI = 0.51-0.86). The AUC based on STEPmetric experienced the largest
111	decrease (delta = -0.12).
112	
113	To assess whether the observed decrease in AUC is consistent with random data

removal or systematic information loss, we further conducted one-sided conditional
permutation tests for each metric (see Methods). In particular, the test assesses the null

116 that, compared to random data removal, no additional decrease in AUC is caused by 117 systematically removing data after receipt of test results. For the STEPmetric, the 118 observed decrease in AUC (step 2, Methods) stands in the left tail of the reference 119 distribution of change in AUC (step 3, Methods; observed change in AUC: -0.12, 120 p=0.013; Extended Data Figure 2c), indicating the observed decrease in AUC by 121 removing post-result data is unlikely a chance event from data reduction and hence the 122 importance of post-result data. Although cases and controls reduced average daily step 123 counts after they became symptomatic, the reduction was significantly more among the cases after receipt of test results (mean change: cases -4,012, controls -1,016; 124 125 p=0.001) and more so than during the symptomatic period before receipt of test results 126 (mean change: cases -2,894, controls -1,083, p=0.03). For RHR and sleep metrics, we 127 did not observe a statistically significant decrease in the AUC after removing the post-128 result data.

129

130 Finally, when only using the post-result-data in the test period (Figure 1c), the AUCs is 131 comparable to the all-data AUC for all metrics (Figure 2i-2l, RHRmetric: 0.62 vs 0.63; 132 SLEEPmetric: 0.63 vs 0.66; STEPmetric: 0.75 vs 0.75; all-sensor: 0.72 vs 0.75), 133 indicating no substantial loss of discriminative accuracy is incurred by only using post-134 result data when defining the metrics. We performed conditional permutation tests as 135 above, but with the number of random days removed being the number of days prior to 136 receipt of test results. No statistically significant decrease in AUCs was observed for 137 any of the metrics (Extended Data Figure 2e-2h).

139 Our analysis reveals the discriminative accuracy of wearable data in COVID-19 140 detection can be explained by behavior changes after receiving test results, more so 141 driven by subjects' within-person change in physical activity, less so by sleep or RHR. In 142 particular, when removing data on and after receipt of test results, the AUC based on 143 STEPmetric drops significantly from the all-data AUC. A small though non-statistically 144 significant drop was observed for SLEEPmetric. No decrease was observed for 145 physiology-based RHRmetric. This pattern is consistent with behavior change after 146 receiving COVID-19 test results. Compared to symptomatic individuals who tested 147 negative, symptomatic individuals who received a positive COVID-19 test may initiate 148 stricter guarantine measures thus reducing activity and aim to get more sleep. It 149 appears that in the short term sleep is more resistant to change than physical activity 150 during the test period, likely strongly regulated by circadian rhythms⁸.

151

152 This study has some limitations. First, our sample is a small subset of symptomatic 153 subjects from a sizable cohort. In future studies, it is critical to aggregate data from 154 multiple studies to further validate and study the variation in AUC with factors that may 155 impact the propensity of behavioral change. Second, the cohort is likely not 156 representative of the entire spectrum of population that may have access to both 157 wearables and tests. However, the unique cohort of medical interns who are likely more 158 adherent to guarantine measures strengthened the specific investigation addressed 159 here. It is of interest to investigate the same question in a broader population. Third, the 160 SARS-CoV-2 tests are not perfectly sensitive or specific. Knowledge about these test-161 related parameters will likely further improve AUC estimates. Fourth, recall of symptom

onset date and test date might not be entirely accurate, but this population of medical
interns is particularly primed to remember the dates due to workplace enforcements of
symptom screening, testing, and compulsory guarantines.

165

166 In a future pandemic, passively-collected wearable data linked with test results may 167 reveal distinct patterns of behavioral change across subpopulations. For example, lack 168 of appropriate behavioral changes upon receiving test results may hurt discriminative 169 accuracy based on wearable sensor data. Variation in the AUC of the step metric by 170 age group may indicate differential levels of within-person change in activity. Groups 171 with higher step-based AUC may have effectively guarantined after receiving their test 172 results; while groups with lower step-based AUC may indicate either delay in their 173 receiving the test results or difficulty and infeasibility in reducing physical activity. 174 Subpopulations with lower observed AUCs may benefit from more targeted public 175 health policy innovations that may promote behavioral change, such as self-quarantine 176 measures.

177

178 Acknowledgements

This study was supported by grants from the National Institute of Mental Health (R01
MH101459) to S.S. and Z.W. and an investigator grant from Precision Health Initiative
at University of Michigan, Ann Arbor to Z.W. and S.S.. J.C. was supported by
T32HD007109. We thank the interns and residency programs who took part in this
study.

184	1
-----	---

185 Author Contributions

- 186 J.C., Y.F., S.S., Z.W. made substantial contributions to the study conception and
- design. S.S. made substantial contributions to the acquisition of data. J.C., Y.F., Z.W.
- 188 conducted statistical analysis. J.C., Y.F., S.S., Z.W. made substantial contributions to
- the interpretation of data. J.C., Y.F., Z.W. drafted the first version of the manuscript.
- 190 J.C., Y.F., S.S., Z.W. contributed to critical revisions and approved the final version of
- the manuscript. J.C., Y.F., S.S., Z.W. take responsibility for the integrity of the work.
- 192

193 Competing Interests Statement

- 194 The authors have no competing interests to disclose.
- 195

196 Data and code availability

- 197 Deidentified data supporting the results and figures in this manuscript are available
- 198 upon reasonable request and completion of a data agreement with the Intern Health
- 199 Study team. Code for data preprocessing and statistical analysis is available upon
- 200 request.
- 201

202 References

- 203 1. Natarajan, A., Su, H.-W. & Heneghan, C. Assessment of physiological signs
- associated with COVID-19 measured using wearable devices. *npj Digital Medicine*
- **3**, 1–8 (2020).
- 206 2. Quer, G. et al. Wearable sensor data and self-reported symptoms for COVID-19

207 detection. *Nat. Med.* **27**, 73–77 (2020).

- Ceren Ates, H., Yetisen, A. K., Güder, F. & Dincer, C. Wearable devices for the
 detection of COVID-19. *Nature Electronics* 4, 13–14 (2021).
- 4. Mishra, T. *et al.* Pre-symptomatic detection of COVID-19 from smartwatch data.
- 211 Nat Biomed Eng **4**, 1208–1220 (2020).
- 5. Radin, J. M., Wineinger, N. E., Topol, E. J. & Steinhubl, S. R. Harnessing wearable
- 213 device data to improve state-level real-time surveillance of influenza-like illness in
- the USA: a population-based study. *Lancet Digit Health* **2**, e85–e93 (2020).
- 215 6. Sen, S. et al. A prospective cohort study investigating factors associated with
- depression during medical internship. *Arch. Gen. Psychiatry* **67**, 557–565 (2010).
- 217 7. NeCamp, T. et al. Assessing Real-Time Moderation for Developing Adaptive Mobile
- Health Interventions for Medical Interns: Micro-Randomized Trial. J. Med. Internet
- 219 *Res.* **22**, e15033 (2020).
- 8. Fang, Y., Forger, D. B., Frank, E., Sen, S. & Goldstein, C. Day-to-day variability in
- sleep parameters and depression risk: a prospective cohort study of training
- physicians. *npj Digital Medicine* **4**, 1–9 (2021).
- 9. The R Project for Statistical Computing. https://www.R-project.org/.

- 225
- 226
- 227
- 228
- 229

230 Methods

-••	
232	Metrics Definition. Participants were drawn from the 2019 and 2020 cohorts of the Intern
233	Health Study. Study recruitment and procedures are detailed elsewhere. ⁸ Briefly,
234	incoming first-year medical residents were surveyed throughout the pandemic from April
235	to December 2020 and asked to report whether and when they experienced any
236	potential COVID-19 symptoms, were tested, and their test results. The sample for this
237	analysis included individuals who reported symptoms and a COVID-19 test, as well as
238	at least 50% of the wearable data (collected through Fitbit or Apple Watch) during both
239	baseline (21 to 7 days prior to symptom onset) and test (0 to 7 days after symptom
240	onset) periods.
241	
242	Following Quer et al. (2020) ² , we calculated metrics for sleep, activity, and resting heart
243	rate (RHR), as well as an overall wearable sensor metric for each participant:
244	
245	RHRmetric = max(dailyRHR[test]) - median(dailyRHR[baseline])/IQR
246	SLEEPmetric = mean(dailySLEEP[test]) - median(dailySLEEP[baseline])/IQR
247	STEPmetric = mean(dailySTEP[test]) - median(dailySTEP[baseline])/IQR
248	SENSORmetric = RHRmetric /10 + SLEEPmetric - STEPmetric
249	Discriminative Accuracy. We calculated ROC curves, AUC, sensitivity (SE), specificity
250	(SP) for each metric to compare the intra-individual change in each metric with

symptom onset between COVID-19 positive and COVID-19 negative individuals. To
assess which part of the test period data is mainly responsible for the realized AUC, we
calculated these parameters in three data schemes: Scheme I - using all the data in
baseline and test periods; Scheme II - removing data on and after receipt of test results
in test periods; Scheme III - removing data before receipt of test results in test periods.

257 *Conditional Permutation Tests.* In order to test the statistical significance of the 258 observed AUC decrease in Scheme II and III, we designed the one-sided conditional 259 permutation tests in a way that breaks the link between the indices of days removed 260 during the test period and the dates of receiving the test results hence creating a null 261 distribution that is adequate for assessing the statistical significance of the observed 262 change in AUC. In particular, for each metric (RHR, sleep, activity, sensor) we perform 263 the following steps:

264

265 Step 1. Calculate AUC based on all the baseline and test of

266 Step 2. Remove part of the test data (on/after receiving the test results as in

Figure 1b; OR before receiving the test results as in Figure 1c), and calculate a

single AUC and the change from the AUC in Step 1;

269 Step 3. Create B=1000 data sets, each by randomly removing the same amount 270 of data for each person as in Step 2; based on each of B random reduced data 271 sets, calculate an AUC and the difference from the AUC in Step 1, resulting in 272 B=1000 values of change in AUC;

273	Step 4. Compare the change of AUC in Step 2 against the null distribution of the
274	change of AUCs in Step 3; Calculate the p-value by the observed fraction among
275	the 1000 randomly reduced data sets that have AUC change less than or equal
276	to the observed change in Step 2.
277	
278	All analyses were conducted using R 4.0.2 ⁹ .
279	
280	
281	
282	
283	
284	
285	
286	
287	
288	
289	
290	
291	
292	
293	
294	
295	



Data Scheme I. Full data set Baseline Symptomatic "test" period (-21 to -7 days to symptom onset) (0 to 7 days since symptom onset) Subject 1 Subject 2 Subject 3 ... Subject N b Data Scheme II. Removing days on and after receiving COVID-19 test results Symptomatic "test" period Baseline (0 to 7 days since symptom onset) (-21 to -7 days to symptom onset) Subject 1 Subject 2 Subject 3 R Subject N R: The day receiving COVID-19 test results С Data Scheme III. Reversed exclusion: removing days before the day receiving COVID-19 test results. Symptomatic "test" period Baseline (-21 to -7 days to symptom onset) (0 to 7 days since symptom onset) Subject 1 R Subject 2 Subject 3 Subject N


296

297 Figure 1. Data Schemes. a-c, green: included data; red: excluded data; R: the day

R: The day receiving COVID-19 test

results

- 298 receiving test results: (a) include all data; (b) exclude data on and after the day
- 299 receiving test results; (c) exclude data before the day receiving test results since
- symptom onset. Ninety-two subjects (87.6%) received their results within the 300
- 301 symptomatic period (0 to 7 days after symptom onset).




302 303

Figure 2. AUCs based on RHR, sleep, activity and all-sensor metric derived from
wearable sensors to differentiate symptomatic subjects who were tested positive
and negative corresponding to data schemes I-III. (a-d): Scheme I - all data; (e-h)
Scheme II - remove data on and after knowing the test results; (i-I): Scheme III remove data since symptom onset and before the test results. For each data scheme in
the row, the four panels are for RHR, sleep, activity and sensor metrics, respectively.

	Including days after the test result (Scheme I)			Excluding days after the test result (Scheme II)			Excluding days before the test result (Scheme III)		
	Test positive	Test negative	P value	Test positive	Test negative	P value	Test positive	Test negative	P value
Demographics									
Number of participants, N	22	83	-	22	75	-	22	82	-
Age, Mean (SD)	28.1 (3.2)	28.7 (2.7)	0.49	28.1 (3.2)	28.7 (2.7)	0.46	28.1 (3.2)	28.6 (2.7)	0.54
Female, N (%)	7 (31.8%)	46 (55.4%)	0.06	7 (31.8%)	41 (54.7%)	0.09	7 (31.8%)	45 (54.9%)	
Fitbit users, N (%)	22 (100%)	82 (98.8%)	-	22 (100%)	74 (98.7%)	-	22 (100%)	81 (98.8%)	-
AppleWatch users, N (%)	0 (0%)	1 (1.2%)	-	0 (0%)	1 (1.3%)	-	0 (0%)	1 (1.2%)	-
Available days during baseline	(IQR)								
RHR	13.4 (11.5-15)	13.7(13-15)	0.55	13.4 (11.5-15)	13.6 (13-15)	0.66	13.4 (11.5-15)	13.7 (13-15)	0.54
Sleep	14.3 (14-15)	13.9(13.5-15)	0.3	14.3 (14-15)	13.9 (13-15)	0.24	14.3 (14-15)	13.9 (13-15)	0.3
Activity	14.9 (15-15)	14.7(15-15)	0.16	14.9 (15-15)	14.7 (15-15)	0.14	14.9 (15-15)	14.7 (15-15)	0.16
Available days during symptor	matic period (IQF	2)							
RHR	7.1 (7.0-8)	7.3 (7-8)	0.66	3.8 (2-6.75)	3.0 (1-4)	0.21	5.1 (3.25-7)	5.2 (4-7)	0.9
Sleep	7.6 (7.3-8)	7.4 (7-8)	0.12	3.9 (2-6.75)	3.0 (1-4)	0.15	5.5 (4-7)	5.3 (4-7)	0.57
Activity	7.9 (8-8)	7.9 (8-8)	0.89	4.0 (2-6.75)	3.1 (1-4)	0.21	5.7 (4-7)	5.7 (4-7)	0.93
Baseline mean (SD)									
RHR (bpm)	60.2 (5.6)	65.3 (7.4)	<0.001	60.2 (5.6)	65.6 (7.4)	<0.001	60.2 (5.6)	65.3 (7.4)	<0.001
Sleep (min)	412 (38)	411 (40)	0.94	412 (38)	411 (41)	0.91	412 (38)	412 (40)	1
Activity (steps)	8650 (2808)	8382 (2366)	0.68	8650 (2808)	8378 (2305)	0.68	8650 (2808)	8400 (2375)	0.7
Symptomatic period mean (SD)								
RHR (bpm)	61.5 (5.6)	65.7 (7.7)	0.007	62.1 (5.5)	66.2 (7.5)	0.007	61.3 (5.7)	65.6 (7.8)	0.005
Sleep (min)	460 (67)	428 (50)	0.046	432 (83)	411 (85)	0.32	469 (75)	433 (57)	0.049
Activity (steps)	4948 (2223)	7344 (2710)	<0.001	5756 (2411)	7295 (3164)	0.02	4638 (2494)	7384 (2902)	<0.001
Mean change (SD)									
RHR (bpm)	1.3 (3.1)	0.4 (2.3)	0.18	1.9 (3.2)	0.5 (2.5)	0.07	1.1 (3.4)	0.3 (2.4)	0.3
Sleep (min)	47.9 (64.8)	16.6 (48.2)	0.044	20 (78)	0.5 (91)	0.33	56.9 (74)	21.4 (49.2)	0.043
Activity (steps)	-3703 (3422)	-1038 (2333)	0.002	-2894 (3327)	-1083 (3140)	0.03	-4012 (3632)	-1016 (2599)	0.001
Metric value (SD)									
RHR	0.36 (0.35)	0.26 (0.27)	0.2	0.26 (0.39)	0.14 (0.25)	0.18	0.33 (0.37)	0.28 (0.27)	0.24
Sleep	0.45 (0.60)	0.19 (0.41)	0.06	0.44 (0.95)	0.24 (0.53)	0.36	0.40 (0.62)	0.17 (0.55)	0.12
Activity	-0.75 (0.69)	-0.18 (0.48)	0.001	-0.63 (0.79)	-0.17 (0.62)	0.02	-0.72 (0.68)	-0.18 (0.51)	0.002
Sensor Metric	1.24 (1.1)	0.40 (0.72)	0.002	1.11 (1.43)	0.42 (0.88)	0.04	1.16 (1.03)	0.37 (0.85)	0.003

Extended Data Figure 1. Summary of key characteristics, metrics and COVID-19 test results.



Extended Data Figure 2. One-sided conditional permutation test for assessing the null that, compared to random data reduction, no additional change in AUC caused by removing data: (a-d) on or after receipt of test result and (e-h) in the symptomatic period and prior to receipt of test results. The random data removal and AUC calculation are done for RHR, sleep, step and the all-sensor data, respectively (shown in four panels in each row). In each panel, the red line indicates the observed change of AUC; the blue line is at zero, indicating no change. The reference distributions are not centered at zero despite data removal being random; because on average there are more days after the receipt of test results than before, random data removal may still impact AUCs. For each metric, if a red line is at the left tail of the histogram, we conclude a statistically significant additional decrease in AUC.